Infant Bacterial Therapeutics AB (IBTb)

Currency in SEK
50.70
+0.20(+0.40%)
Closed·
IBTb Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IBTb is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
50.0051.20
52 wk Range
21.70132.50
Key Statistics
Prev. Close
50.5
Open
51.2
Day's Range
50-51.2
52 wk Range
21.7-132.5
Volume
3.91K
Average Volume (3m)
8.55K
1-Year Change
-56.84%
Book Value / Share
11.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IBTb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Infant Bacterial Therapeutics AB Company Profile

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.

Employees
8
Market
Sweden

Compare IBTb to Peers and Sector

Metrics to compare
IBTb
Peers
Sector
Relationship
P/E Ratio
−5.4x−3.7x−0.5x
PEG Ratio
−0.900.190.00
Price/Book
4.4x−1.9x2.6x
Price / LTM Sales
−683,001.0x−378,712.8x3.3x
Upside (Analyst Target)
-0.0%45.1%
Fair Value Upside
Unlock−44.3%7.4%Unlock

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-1.24 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IBTb Income Statement

FAQ

What Stock Exchange Does Infant Bacterial Therapeutics Trade On?

Infant Bacterial Therapeutics is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Infant Bacterial Therapeutics?

The stock symbol for Infant Bacterial Therapeutics is "IBTb."

What Is the Infant Bacterial Therapeutics Market Cap?

As of today, Infant Bacterial Therapeutics market cap is 683.00M.

What Is Infant Bacterial Therapeutics's Earnings Per Share (TTM)?

The Infant Bacterial Therapeutics EPS (TTM) is -9.34.

From a Technical Analysis Perspective, Is IBTb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Infant Bacterial Therapeutics Stock Split?

Infant Bacterial Therapeutics has split 2 times.

How Many Employees Does Infant Bacterial Therapeutics Have?

Infant Bacterial Therapeutics has 8 employees.

What is the current trading status of Infant Bacterial Therapeutics (IBTb)?

As of 04 Aug 2025, Infant Bacterial Therapeutics (IBTb) is trading at a price of 50.70, with a previous close of 50.50. The stock has fluctuated within a day range of 50.00 to 51.20, while its 52-week range spans from 21.70 to 132.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.